<!DOCTYPE html>
<html>
<head>
  <title>RAPID Research Group</title>
  <link rel="stylesheet" href="style.css">
</head>
<body>

<header class="site-header">
  <div class="brand">
    <a href="index.html" class="brand-link">
      <img src="logo.png" alt="RAPID logo" class="logo">
    </a>
    <div class="brand-text">
      <h1>RAPID</h1>
      <p>Research in Applied Pharmacokinetics and Individualised Dosing</p>
    </div>
  </div>

  <nav class="nav">
    <a href="index.html">Home</a>
    <a href="about.html">About</a>
    <a href="people.html">People</a>
    <a href="research.html">Research</a>
    <a href="activities.html">Activities</a>
    <a href="publications.html">Publications</a>
    <a href="collaborate.html">Collaborate</a>
    <a href="contact.html">Contact</a>
  </nav>
</header>

<section>
  <h2 style="text-align:center;">Optimising dosing, improving patient outcomes</h2>
  <p style="text-align:center; max-width:900px; margin: 0 auto;">
    RAPID is a collaborative research group at the Faculty of Pharmacy, UKM.
    We use pharmacokinetics, pharmacometrics, and pharmacogenetics to support
    individualised dosing and clinical decision-making.
  </p>
</section>

<section>
  <h2>Current focus areas</h2>
  <p class="small">
    These are our ongoing project areas right now â€” but we are open to collaboration in <strong>any therapeutic area</strong>
    where PK/PD, TDM, pharmacogenetics, or assay-linked research can improve dosing.
  </p>

  <div class="cards">
    <div class="card">
      <div class="icon">ðŸ©¸</div>
      <h3>Thrombosis & Haemostasis</h3>
      <p>Anticoagulants, exposure variability, and precision dosing in real-world populations.</p>
      <p class="small"><strong>Typical work:</strong> PK variability, TDM questions, dose optimisation.</p>
    </div>

    <div class="card">
      <div class="icon">ðŸ§¬</div>
      <h3>Oncology</h3>
      <p>PK-guided therapy, toxicity risk, and dosing optimisation for cancer treatments.</p>
      <p class="small"><strong>Typical work:</strong> methotrexate risk prediction, PK/PD, assay-linked studies.</p>
    </div>

    <div class="card">
      <div class="icon">ðŸ¦ </div>
      <h3>Antibiotics</h3>
      <p>Model-informed antimicrobial dosing, especially in critically ill and special populations.</p>
      <p class="small"><strong>Typical work:</strong> PopPK, CRRT dosing, target attainment.</p>
    </div>
  </div>
</section>

<section>
  <h2>What we work on</h2>
  <div class="cards">
    <div class="card">
      <div class="icon">ðŸ“ˆ</div>
      <h3>PK / PopPK / PKPD</h3>
      <p>Modelling, simulation, covariates, and dose optimisation.</p>
    </div>
    <div class="card">
      <div class="icon">ðŸ§ª</div>
      <h3>TDM</h3>
      <p>Designing and interpreting therapeutic drug monitoring studies.</p>
    </div>
    <div class="card">
      <div class="icon">ðŸ§¬</div>
      <h3>Pharmacogenetics</h3>
      <p>Linking genotype to exposure and clinical outcomes.</p>
    </div>
    <div class="card">
      <div class="icon">ðŸ§«</div>
      <h3>Assay-linked research</h3>
      <p>Connecting concentrations with outcomes using validated assays.</p>
    </div>
  </div>
</section>

<footer>
  Centre for Quality Management of Medicines, Faculty of Pharmacy UKM
</footer>

</body>
</html>
